CEO interviewed on CNBC this am... the market was expecting 50% with the first test and the 'product' only does ~42% which is still significant considering it's comparison to cervical cancer pre-screening capabilities. The uncertainty is probably due to whether it will offset the income doctors receive from recommending colonoscopy procedures now. If it's significantly less than there won't be a significant push by doctors, even though it provides a much earlier detection rate.
EXAS: Had high expectations with 600million cap, also even if precancerous polyps detected need the colonoscopy to remove...... Most people will always have some polyps for removal so unless test more accurate why is it worth more than 600 million right now?
Market Data 
Markets 
